Illumina, Inc.
5200 Illumina Way
San Diego
California
92122
United States
Tel: 858-202-4500
Website: http://www.illumina.com/
About Illumina, Inc.
Illumina is improving the future of human health by unlocking the power of the genome. Our mission is everything to us. We are deeply passionate about what we do because we know we are solving problems that really matter. Our people and technology change lives by pioneering advancements in life sciences, oncology, reproductive health, agriculture, forensic genomics, and much more. Working in such critical fields requires industry-leading support, service, and scalability, and we strive to meet these challenges by collaborating across groups, business units, and locations. We are growing rapidly and looking for great talent to join Illumina.
We invite you to explore our career opportunities: https://www.illumina.com/company/careers.html
Key Management:
Jay T. Flatley - Executive Chairman
Francis deSouza - President & Chief Executive Officer
Garret Hampton, PhD - Executive Vice President, Clinical Genomics
Omead Ostadan - Executive Vice President, Operations, Products & Strategy
Marc Stapley - Executive Vice President & Chief Administrative Officer
Charles Dadswell - Senior Vice President & General Counsel
Mostafa Ronaghi, PhD - Senior Vice President & Chief Technology Officer
Sam Samad - Senior Vice President & Chief Financial Officer
Mark Van Oene - Senior Vice President & Chief Commercial Officer
Stock Symbol: ILMN
Stock Exchange: NASDAQ
Life at Illumina
847 articles with Illumina, Inc.
-
The new division would benefit from Hahn's experience and help steer the company's Preemptive Medicine and Health Security initiative.
-
DNA Data Storage Alliance Publishes First White Paper, Launches Website
6/10/2021
The DNA Data Storage Alliance, an organization of more than 25 leading companies formed by Twist Bioscience Corporation, Illumina, Inc. and Western Digital together with Microsoft Research, announced its first white paper titled “Preserving our Digital Legacy: An Introduction to DNA Data Storage.”.
-
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
-
Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis
6/1/2021
Illumina, Inc. announced an agreement with the Belgian Genetic Centers to evaluate whole-genome sequencing for the diagnosis of patients with intellectual disabilities and/or developmental disorders in routine care.
-
Illumina To Webcast Upcoming Investor Conference - May 27, 2021
5/27/2021
Illumina, Inc. announced that its executives will be speaking at the following investor conference
-
Microba Life Sciences and Illumina partner to accelerate microbiome research
5/25/2021
Leaders in precision gut microbiome science Microba Life Sciences has united with Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies to advance understanding of the human gut microbiome in human health and disease.
-
Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development
5/17/2021
Illumina, Inc. (NASDAQ: ILMN) today announced that it is appointing Susan Tousi as Chief Commercial Officer (CCO), and Dr. Alex Aravanis as Chief Technology Officer (CTO), Head of Research and Product Development.
-
BioSpace takes an in-depth look at the Top 25 of Q1.
-
Illumina To Webcast Upcoming Investor Conference
4/29/2021
Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
-
Illumina Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition
4/29/2021
Illumina, Inc. announced that it has filed an action in the General Court of the European Union asking for annulment of the European Commission’s decision asserting jurisdiction to review Illumina’s acquisition of GRAIL.
-
Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative
4/28/2021
Illumina, Inc. (NASDAQ: ILMN) has committed US $60 million in sequencing capabilities to a global pathogen genomics initiative, in partnership with the Bill & Melinda Gates Foundation and other public and private entities
-
Illumina Reports Financial Results for First Quarter of Fiscal Year 2021
4/27/2021
Illumina, Inc. announced its financial results for the first quarter of fiscal year 2021.
-
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and Astra...
-
Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic
4/22/2021
Illumina, Inc. (NASDAQ: ILMN) and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s comprehensive genomic profiling assay, TruSight™ Oncology 500 (TSO 500). This companion diagnostic for multiple hematologic indications will be the first to use TSO 500 with peripheral whole blood as a diagnostic sample type.
-
Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
4/20/2021
Illumina, Inc., announced that it disagrees with the European Commission’s Directorate-General for Competition’s decision to review Illumina’s acquisition of GRAIL, a company founded to accelerate early screening of cancer.
-
Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021
4/5/2021
Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2021 and updated its fiscal year 2021 revenue guidance. Subject to quarter-end closing adjustments, Illumina expects to report first quarter 2021 revenue of approximately $1,085 million, compared to $859 million in the first quarter of 2020.
-
Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
3/30/2021
Illumina, Inc. (NASDAQ: ILMN), today announced that it disagrees with, and will oppose, the U.S. Federal Trade Commission (FTC)’s challenge to its previously announced acquisition of GRAIL, a pre-commercial company founded to accelerate early screening of cancer.
-
Antitrust Concerns Hinder Second Illumina Acquisition, FTC Raises Concern Over $8 Billion Deal fo...
3/30/2021
Illumina plans to continue to pursue its acquisition of Grail Inc. despite the objection of the U.S. Federal Trade Commission. -
Illumina Announces Board Changes
3/18/2021
Illumina, Inc. (NASDAQ: ILMN) (the “Company”) today announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Company’s new Chair of the Board.
-
Geneseeq Inks Deal with Illumina to Develop and Commercialize Comprehensive Cancer In-vitro Diagnostic NGS Kit in China
3/16/2021
Next-generation sequencing (NGS)-based precision oncology provider Geneseeq Technology Inc. ("Geneseeq"), will collaborate with Illumina, Inc. (NASDAQ: ILMN) ("Illumina") to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer, using Illumina's NextSeq™ 550Dx sequencing platform